Bio-Rad’s Bio-Plex Pro Human IgG SARS-CoV-2 N/RBD/S1/S2 4-Plex Panel is a ready-to-use, qualitative multiplex immunoassay panel which has been designed to provide quick, precise detection of IgG antibodies against four SARS-CoV-2 antigens. This “provides useful information about natural exposure rates in a population or about vaccine immunogenicity,” said Candice Cox, Bio-Rad Immunoassays Marketing Manager, Life Science Group.
Bio-Rad says that vaccine developers can use this information to understand both the strength of response and antibody levels at different developmental stages after SARS-CoV-2 infection or vaccination, as well as determine therapeutic efficacy. Additionally, public health researchers can perform seroprevalence studies.
Use of the kit could assist in the identification of the number of persons in a population who have been exposed to SARS-CoV-2 based on serology specimens, capturing individuals who have not received a COVID-19 diagnosis due to experiencing only mild symptoms or being asymptomatic.
The 96-well kit contained premixed magnetic capture beads (which can be used to measure antibodies in any species, making the assay useful for both preclinical and clinical trials), an IgG-specific detection antibody which detects based on median fluorescence intensity (MFI) cutoff values, positive and negative controls, and buffers that produce results for four anti–SARS-Cov-2 antibodies using only 5 microliters of sample. It includes singleplex assay reagents, enabling measurement of specific viral antigens of interest, and improves laboratory efficiency by generating key actionable data in a single experiment. The kit is compatible with RUO Bio-Rad platforms, including the Bio-Plex 200 and Bio-Plex 3D Multiplex Immunoassay Systems, as well as all other RUO xMAP platforms.
